The World Alzheimer's Disease Market (Incidence, Treatments, Key Companies, Pipeline and Trends)

Below is the list of sections extracted directly from the report. Please note this list has been standardized and may not match the Table of Contents.

• Executive Summary
  • BACKGROUND
  • SCOPE AND METHODOLOGY
  • SIZE AND GROWTH OF THE MARKET
  • KEY ISSUES AND TRENDS AFFECTING MARKET
  • LEADING COMPETITORS
• Introduction
  • OVERVIEW
  • STRUCTURAL ORGANIZATION OF THE NEUROLOGICAL SYSTEM
    • Central Nervous System
  • AGING AND ALZHEIMER'S DISEASE
  • STAGES OF ALZHEIMER'S DISEASE
    • (Table) Alzheimer's Disease Stages 1-7 and Descriptions
  • RISK FACTORS
  • LIFE EXPECTANCY AND THE GROWING INCIDENCE OF ALZHEIMER'S DISEASE
    • (Table) Average Life Expectancy in Years by Country 1980, 2004 and 2006 (years)
  • WORLD DEMOGRAPHICS
    • (Table) World Population by Selected Geographical Region, 2007 - 2050
    • (Table) Estimated World Population by Age and Geographical Region, 2007
    • (Table) Percent Population Over 65 by Year and Region
    • (Table) Estimated World Population by Age, 2007 and 2050
  • PREVALENCE,INCIDENCE AND MORTALITY
    • (Table) Estimated Prevalence, Incidence and Mortality for Alzheimer's Disease* by Region/Country, 2007
  • INSURANCE FOR THE ELDERLY IN THE UNITED STATES
    • (Table) Health Insurance Trends in the United States, Estimated 2007 (millions)
  • GENERIC COMPETITION
    • Teva/Mutual Pharmaceutical/United Research Laboratories and Eisai
    • Dr. Reddy's and Novartis
    • Ranbaxy and Ortho-McNeil Neurologics
• Alzheimer's Disease Product Analysis
  • OVERVIEW OF PRODUCTS
    • (Table) Comparison of Marketed Alzheimer's Disease Treatments
  • ARICEPT
  • NAMENDA/EXIBA/AXURA
  • EXELON
  • RAZADYNE
  • OTHER PRODUCTS
• Research and Development
  • OVERVIEW
    • Phase III
    • Phase II
    • Phase I
    • Preclinical Development
      • (Table) Alzheimer's Disease Therapies in Development
• Market and Competitor Analysis
  • MARKET OVERVIEW
    • (Table) Alzheimer's Disease Market Analysis, 2005-2007 (in millions of dollars at the manufacturer's level)
    • (Table) Forecasted Alzheimer's Disease Market Analysis: 2008-2012 (in millions of dollars at the manufacturer's level)
    • Market Analysis by Product Type
      • (Table) Alzheimer's Disease Market Analysis by Drug Type, 2005-2007 (Cholinesterase inhibitors, NMDA antagonists) (in millions of dollars at the manufacturers' level)
      • (Table) Alzheimer's Disease Market Share by Drug Type, 2005
      • (Table) Alzheimer's Disease Market Share by Drug Type, 2007
    • Market Analysis by Country
      • (Table) Alzheimer's Disease Market Analysis by Region/Country, 2007
    • Competitive Analysis
      • (Table) Alzheimer's Disease Market Estimated Revenues and Market Share of Leading Suppliers 2007
    • Leading Products
      • (Table) Alzheimer's Disease Market Estimated Sales of Top Products 2007
• Leading Manufacturers
  • OVERVIEW
  • EISAI CO., LTD.
    • (Table) Eisai's Net Revenues and R&D Expenses for 2006 and 2007 Millions
  • FOREST LABORATORIES
    • (Table) Forest's Net Revenues and R&D Expenses for 2006 and 2007 Millions
  • H. LUNDBECK A/S
    • (Table) Lundbeck's Net Revenues and R&D Expenses for 2006 and 2007 Millions
  • JOHNSON &JOHNSON
    • (Table) Johnson & Johnson's Net Revenues and R&D Expenses for 2006 and 2007 Millions
  • MERZ PHARMA GMBH
    • (Table) Merz Pharma's Net Revenues and R&D Expenses for 2006 and 2007 Millions
  • NOVARTIS AG
    • (Table) Novartis' Net Revenues and R&D Expenses for 2006 and 2007 Millions
  • PFIZER,INC.
    • (Table) Pfizer's Net Revenues and R&D Expenses for 2006 and 2007 Millions
• List of Major Companies